<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04965532</url>
  </required_header>
  <id_info>
    <org_study_id>2020-046</org_study_id>
    <nct_id>NCT04965532</nct_id>
  </id_info>
  <brief_title>Residual Neuromuscular Block of Rocuronium in Chemotherapy Patients Under Sevoflurane Anesthesia</brief_title>
  <official_title>Second Affiliated Hospital Zhejiang University School of Medicine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Second Affiliated Hospital, School of Medicine, Zhejiang University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Second Affiliated Hospital, School of Medicine, Zhejiang University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Chemotherapy causes motor nerve dysfunction and degeneration that may alter the response to&#xD;
      neuromuscular blocking drugs. To analyse the risk of residual neuromuscular block (RNMB)&#xD;
      induced by rocuronium given in standard doses to patients who undergo chemotherapy within&#xD;
      three months.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Rocuronium, as a non depolarizing muscle relaxant with medium time effect, takes effect&#xD;
      rapidly. It is an ideal neuromuscular blocker to replace succinylcholine for induction of&#xD;
      tracheal intubation and maintenance of muscle relaxant under general anesthesia. Sevoflurane&#xD;
      is widely used in clinic because of its low blood gas partition coefficient, rapid and stable&#xD;
      induction and recovery, easy adjustment of anesthesia depth and strong controllability. In&#xD;
      addition, the number of patients receiving preoperative adjuvant chemotherapy for malignant&#xD;
      tumors is increasing year by year in China. The commonly used chemotherapy drugs, such as&#xD;
      paclitaxel, platinum, vinorelbine, etc., have dose-dependent peripheral neurotoxicity.&#xD;
      Therefore, to explore and study the influence of pathophysiological changes of patients&#xD;
      receiving chemotherapy on the neuromuscular relaxation effect of sevoflurane combined with&#xD;
      non depolarizing neuromuscular blockers, It is very important for anesthesia, resuscitation&#xD;
      and perioperative management of chemotherapy patients. The purpose of this study is to reveal&#xD;
      the effect of sevoflurane on rocuronium neuromuscular blockade in chemotherapy patients by&#xD;
      comparing the difference of rocuronium neuromuscular blockade effect of sevoflurane and total&#xD;
      intravenous anesthesia in chemotherapy patients and non chemotherapy patients, and to provide&#xD;
      information for more safe and rational application of rocuronium in clinical anesthesia of&#xD;
      chemotherapy patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2021</start_date>
  <completion_date type="Anticipated">August 31, 2022</completion_date>
  <primary_completion_date type="Anticipated">February 28, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Eighty patients undergoing liver radiofrequency ablation surgery under elective general anesthesia were selected, of whom 40 received preoperative adjuvant chemotherapy and the other 40 were nonchemotherapy patients, who were divided by randomization according to the method of anesthesia maintenance, respectively.Chemotherapy patients were divided into PC group with 20 cases using all intravenous anesthesia and SC group with 20 cases using sevoflurane anesthesia.The nonchemotherapy patients were divided into PN group with 20 cases using all intravenous anesthesia and Sn group with 20 cases using sevoflurane anesthesia.</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Muscle relaxation recovery index</measure>
    <time_frame>The first 90 min following intravenous injection of rocuronium</time_frame>
    <description>Time interval from 25% recovery to 75% recovery of the first twitch in the TOF stimulation pattern</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Onset time of muscle relaxation</measure>
    <time_frame>The first 90 min following intravenous injection of rocuronium</time_frame>
    <description>Time interval from the completion of intravenous injection of rocuronium to the maximal depression of the first twitch in the TOF stimulation pattern</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Clinical duration of muscle relaxation</measure>
    <time_frame>The first 90min following intravenous injection of rocuronium</time_frame>
    <description>Time interval from the completion of intravenous injection of rocuronium to 25% recovery of the first twitch in the TOF stimulation pattern</description>
  </other_outcome>
  <other_outcome>
    <measure>TOF ratio</measure>
    <time_frame>10min following intravenous injection of rocuronium</time_frame>
    <description>Dividing the amplitude of the fourth response by the amplitude of the first response</description>
  </other_outcome>
  <other_outcome>
    <measure>T1 amplitude</measure>
    <time_frame>10min following intravenous injection of rocuronium</time_frame>
    <description>The amplitude of the first twitch to TOF stimulation</description>
  </other_outcome>
  <other_outcome>
    <measure>TOF ratio</measure>
    <time_frame>20min following intravenous injection of rocuronium</time_frame>
    <description>Dividing the amplitude of the fourth response by the amplitude of the first response</description>
  </other_outcome>
  <other_outcome>
    <measure>T1 amplitude</measure>
    <time_frame>20min following intravenous injection of rocuronium</time_frame>
    <description>The amplitude of the first twitch to TOF stimulation</description>
  </other_outcome>
  <other_outcome>
    <measure>TOF ratio</measure>
    <time_frame>30min following intravenous injection of rocuronium</time_frame>
    <description>Dividing the amplitude of the fourth response by the amplitude of the first response</description>
  </other_outcome>
  <other_outcome>
    <measure>T1 amplitude</measure>
    <time_frame>30min following intravenous injection of rocuronium</time_frame>
    <description>The amplitude of the first twitch to TOF stimulation</description>
  </other_outcome>
  <other_outcome>
    <measure>TOF ratio</measure>
    <time_frame>40min following intravenous injection of rocuronium</time_frame>
    <description>Dividing the amplitude of the fourth response by the amplitude of the first response</description>
  </other_outcome>
  <other_outcome>
    <measure>T1 amplitude</measure>
    <time_frame>40min following intravenous injection of rocuronium</time_frame>
    <description>The amplitude of the first twitch to TOF stimulation</description>
  </other_outcome>
  <other_outcome>
    <measure>TOF ratio</measure>
    <time_frame>50min following intravenous injection of rocuronium</time_frame>
    <description>Dividing the amplitude of the fourth response by the amplitude of the first response</description>
  </other_outcome>
  <other_outcome>
    <measure>T1 amplitude</measure>
    <time_frame>50min following intravenous injection of rocuronium</time_frame>
    <description>The amplitude of the first twitch to TOF stimulation</description>
  </other_outcome>
  <other_outcome>
    <measure>TOF ratio</measure>
    <time_frame>60min following intravenous injection of rocuronium</time_frame>
    <description>Dividing the amplitude of the fourth response by the amplitude of the first response</description>
  </other_outcome>
  <other_outcome>
    <measure>T1 amplitude</measure>
    <time_frame>60min following intravenous injection of rocuronium</time_frame>
    <description>The amplitude of the first twitch to TOF stimulation</description>
  </other_outcome>
  <other_outcome>
    <measure>TOF ratio</measure>
    <time_frame>70min following intravenous injection of rocuronium</time_frame>
    <description>Dividing the amplitude of the fourth response by the amplitude of the first response</description>
  </other_outcome>
  <other_outcome>
    <measure>T1 amplitude</measure>
    <time_frame>70min following intravenous injection of rocuronium</time_frame>
    <description>The amplitude of the first twitch to TOF stimulation</description>
  </other_outcome>
  <other_outcome>
    <measure>TOF ratio</measure>
    <time_frame>80min following intravenous injection of rocuronium</time_frame>
    <description>Dividing the amplitude of the fourth response by the amplitude of the first response</description>
  </other_outcome>
  <other_outcome>
    <measure>T1 amplitude</measure>
    <time_frame>80min following intravenous injection of rocuronium</time_frame>
    <description>The amplitude of the first twitch to TOF stimulation</description>
  </other_outcome>
  <other_outcome>
    <measure>TOF ratio</measure>
    <time_frame>90min following intravenous injection of rocuronium</time_frame>
    <description>Dividing the amplitude of the fourth response by the amplitude of the first response</description>
  </other_outcome>
  <other_outcome>
    <measure>T1 amplitude</measure>
    <time_frame>90min following intravenous injection of rocuronium</time_frame>
    <description>The amplitude of the first twitch to TOF stimulation</description>
  </other_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">80</enrollment>
  <condition>Chemotherapeutic Toxicity</condition>
  <arm_group>
    <arm_group_label>chemotherapy patients using sevoflurane anesthesia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following induction of anesthesia and laryngeal mask placement, anesthesia will be maintained by inhalation of sevoflurane (approximately 1.3 × minimum alveolar concentration) and IV fentanyl according to clinical need.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>chemotherapy patients using total intravenous anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following induction of anesthesia and laryngeal mask placement, maintenance of anesthesia will consist of target-controlled infusion of propofol at a plasma target concentration of 1.5-3.0µg/ml and IV fentanyl according to clinical need.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nonchemotherapy patients using sevoflurane anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following induction of anesthesia and laryngeal mask placement, anesthesia will be maintained by inhalation of sevoflurane (approximately 1.3 × minimum alveolar concentration) and IV fentanyl according to clinical need.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nonchemotherapy patient using total intravenous anesthesia</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Following induction of anesthesia and laryngeal mask placement, maintenance of anesthesia will consist of target-controlled infusion of propofol at a plasma target concentration of 1.5-3.0µg/ml and IV fentanyl according to clinical need.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>sevoflurane anesthesia</intervention_name>
    <description>Sevoflurane enhances the effects of rocuronium and significantly prolongs the duration of action of rocuronium and the time to recovery.</description>
    <arm_group_label>chemotherapy patients using sevoflurane anesthesia</arm_group_label>
    <arm_group_label>nonchemotherapy patients using sevoflurane anesthesia</arm_group_label>
    <other_name>inhalation anesthesia</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propofol Injection</intervention_name>
    <description>Propofol is most commonly used for intravenous anesthesia. In contrast to sevoflurane, propofol has no effects on rocuronium.</description>
    <arm_group_label>chemotherapy patients using total intravenous anesthesia</arm_group_label>
    <arm_group_label>nonchemotherapy patient using total intravenous anesthesia</arm_group_label>
    <other_name>intravenous anesthesia</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients classified as American Society of Anesthesiology physical status (ASA PS)&#xD;
             classes I, II or III&#xD;
&#xD;
          -  Aged between 18 and 70 years&#xD;
&#xD;
          -  Scheduled for radiofrequency ablation of liver tumours under general anaesthesia with&#xD;
             an expected surgery duration shorter than 60min&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Allergy to rocuronium&#xD;
&#xD;
          -  Myasthenia gravis&#xD;
&#xD;
          -  Guillain-Barre ́ syndrome&#xD;
&#xD;
          -  Duchenne muscular dystrophy or similar&#xD;
&#xD;
          -  Receiving drugs that might interfere with the neuromuscular transmission or the&#xD;
             response to neuromuscular blockers, such as some anticonvulsants and antibiotics&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lili Fang, Dr.</last_name>
    <role>Principal Investigator</role>
    <affiliation>Second Affiliated Hospital Zhejiang University School of Medicine</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lili Fang, Dr.</last_name>
    <phone>+8615068892166</phone>
    <email>fanglili@zju.edu.cn</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huzhou Central Hospital</name>
      <address>
        <city>Huzhou</city>
        <state>Zhejiang</state>
        <zip>313000</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Huanzhong He, Dr.</last_name>
      <phone>13857270631</phone>
      <email>hhzhma@sina.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Quzhou People's Hospital</name>
      <address>
        <city>Quzhou</city>
        <state>Zhejiang</state>
        <zip>324002</zip>
        <country>China</country>
      </address>
    </facility>
    <contact>
      <last_name>Yunping Lan, Dr.</last_name>
      <phone>15657063766</phone>
      <email>qzmzzk@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 6, 2021</study_first_submitted>
  <study_first_submitted_qc>July 11, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">July 16, 2021</study_first_posted>
  <last_update_submitted>July 11, 2021</last_update_submitted>
  <last_update_submitted_qc>July 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">July 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Propofol</mesh_term>
    <mesh_term>Sevoflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

